Clinical trials monitoring
This article was originally published in The Gray Sheet
Executive SummaryFDA public meeting slated for Nov. 27 at the Hyatt Regency in Bethesda, Maryland will solicit comments on the draft "Guidance for Clinical Trial Sponsors: On the Establishment and Operation of Clinical Trial Data Monitoring Committees." 1FDA's guidance, which details the roles, responsibilities and operating procedures of DMCs, is posted at 2http://www.fda.gov/cber/gdlns/clindatmon.htm...
You may also be interested in...
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.
Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.
It has been a long and sometimes tortuous development path for Lupuzor but ImmuPharma's chief executive tells Scrip the company's faith in the lupus drug is bearing fruit.